BMO Capital Downgrades Pfizer (PFE) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to BMO Capital Downgrades Pfizer (PFE) to Market Perform
November 2, 2016 7:54 AM EDT
Argus downgraded Pfizer (NYSE: PFE) from Buy to Hold on a weaker outlook.
The analyst no longer expect PFE to achieve their former target price of $39 given recent pipeline setbacks, prospects for increased competition, and managements decision to shelve its business separation... More
November 1, 2016 6:46 AM EDT
Pfizer (NYSE: PFE) reported Q3 EPS of $0.61, $0.01 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $13.05 billion versus the consensus estimate of $13.05 billion.
Prevnar revenue was $1.54 billion, versus $1.46 billion expectedIbrance revenue was $550 million, versus $548.4 million expected.
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our business continues to perform well as demonstrated by the quarters financial results. Our Innovative Health business executed strongly behind the latest product launches, and our two recent acquisitions -- Medivation and Anacor -- are providing new near-term... More
